<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-11-30" updated="2020-01-02">
  <drugbank-id primary="true">DB09422</drugbank-id>
  <name>Soybean oil</name>
  <description>Derived from soybeans, soybean oil is a common vegetable oil and a source of polyunsaturated and saturated fatty acids. It is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat. The major component fatty acids are linoleic (48% - 58%), oleic (17% - 30%), palmitic (9% -13%), linolenic (4% - 11%), and stearic (2.5% - 5.0%). It is used as a cooking oil and lipid emulsion for parenteral nutrition in clinical settings. Soybean oil-based lipid emulsion is the only FDA-approved lipid formulation for clinical use.</description>
  <cas-number/>
  <unii>241ATL177A</unii>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A19585</ref-id>
        <pubmed-id>22488002</pubmed-id>
        <citation>Umpierrez GE, Spiegelman R, Zhao V, Smiley DD, Pinzon I, Griffith DP, Peng L, Morris T, Luo M, Garcia H, Thomas C, Newton CA, Ziegler TR: A double-blind, randomized clinical trial comparing soybean oil-based versus olive oil-based lipid emulsions in adult medical-surgical intensive care unit patients requiring parenteral nutrition. Crit Care Med. 2012 Jun;40(6):1792-8. doi: 10.1097/CCM.0b013e3182474bf9.</citation>
      </article>
      <article>
        <ref-id>A19586</ref-id>
        <pubmed-id>21832112</pubmed-id>
        <citation>Siqueira J, Smiley D, Newton C, Le NA, Gosmanov AR, Spiegelman R, Peng L, Osteen SJ, Jones DP, Quyyumi AA, Ziegler TR, Umpierrez GE: Substitution of standard soybean oil with olive oil-based lipid emulsion in parenteral nutrition: comparison of vascular, metabolic, and inflammatory effects. J Clin Endocrinol Metab. 2011 Oct;96(10):3207-16. doi: 10.1210/jc.2011-0480. Epub 2011 Aug 10.</citation>
      </article>
      <article>
        <ref-id>A19587</ref-id>
        <pubmed-id>20473991</pubmed-id>
        <citation>Jiang ZM, Wilmore DW, Wang XR, Wei JM, Zhang ZT, Gu ZY, Wang S, Han SM, Jiang H, Yu K: Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. Br J Surg. 2010 Jun;97(6):804-9. doi: 10.1002/bjs.6999.</citation>
      </article>
      <article>
        <ref-id>A19588</ref-id>
        <pubmed-id>20531018</pubmed-id>
        <citation>Tomsits E, Pataki M, Tolgyesi A, Fekete G, Rischak K, Szollar L: Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):514-21. doi: 10.1097/MPG.0b013e3181de210c.</citation>
      </article>
      <article>
        <ref-id>A19591</ref-id>
        <pubmed-id>16651709</pubmed-id>
        <citation>Nishimura M, Yamaguchi M, Naito S, Yamauchi A: Soybean oil fat emulsion to prevent TPN-induced liver damage: possible molecular mechanisms and clinical implications. Biol Pharm Bull. 2006 May;29(5):855-62.</citation>
      </article>
      <article>
        <ref-id>A19592</ref-id>
        <pubmed-id>26630252</pubmed-id>
        <citation>Kapoor V, Glover R, Malviya MN: Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants. Cochrane Database Syst Rev. 2015 Dec 2;(12):CD009172. doi: 10.1002/14651858.CD009172.pub2.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L853</ref-id>
        <title>SMOFLIPID (lipid injectable emulsion) FDA Label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207648lbl.pdf</url>
      </link>
      <link>
        <ref-id>L855</ref-id>
        <title>NUTRILIPIDÂ® (lipid injectable emulsion) FDA Label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019531s002lbl.pdf</url>
      </link>
      <link>
        <ref-id>L854</ref-id>
        <title>CLINOLEIC 20% (Lipid Emulsion for Intravenous Nutrition) FDA Label</title>
        <url>http://www.baxter.ca/en_CA/assets/downloads/monographs/ClinOleic_PM_30Jul2014_EN.pdf</url>
      </link>
      <link>
        <ref-id>L856</ref-id>
        <title>INTRALIPID (soybean oil emulsion) Dailymed drug label information</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b007eb60-e18e-4dbc-bf8d-1a3cf434a722</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated for parenteral nutrition as a source of calories and essential fatty acids when oral or enteral nutrition is not possible, insufficient, or contraindicated. </indication>
  <pharmacodynamics>Soybean oil is a nutrition source that provides a biologically utilizable source of calories and essential fatty acids. It prevents the biochemical lesions of essential fatty acid deficiency (EFAD), and correct the clinical manifestations of the EFAD syndrome [L856] by supplying energy and nutrients. </pharmacodynamics>
  <mechanism-of-action>Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are also important for membrane structure and function, precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression. Soybean oil-based lipid emulsion may also cause an increase in heat production, decrease in respiratory quotient, and increase in oxygen consumption following its administration [L855]. Soybean oil contents prevent abnormally high triacylglycerol synthesis and its accumulation as lipid droplets in the liver by regulating hepatic lipogenesis and lipolysis. In vitro, soybean oil is shown to prevent downregulation of CYP2C2, CYP2C11 and CYP3A2 mRNA thus maintaining hepatic drug oxidation capabilities. Soybean oil is broken down into free fatty acids that activate PPAR-alpha, which regulate hepatic CYP4A1 that hydroxylate saturated and unsaturated fatty acids. Soybean oil is also shown to prevent up/downregulation of efflux transporters and maintain mRNA levels of hepatic antioxidant enzymes in vitro rat studies [A19591]. </mechanism-of-action>
  <toxicity>The most frequent adverse effects were nausea, vomiting and muscle spasm. Soybean oil-based lipid emulsions can cause hypersensitivity reactions and risks of catheter-related infections. Fat overload syndrome is a rare condition that has been reported with intravenous lipid emulsions, due to a reduced or limited ability to metabolize lipids accompanied by prolonged plasma clearance. Worsensing conditions of the patients can be seen including hematological effects, declined hepatic function and central nervous system manifestations. Hypertriglyceridema may occur. Preterm and small-for-gestational-age infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion, leading to accumulation in lungs. It is advised not to exceed 0.75 mL/kg/hour. </toxicity>
  <metabolism>The infused lipid particles are removed from the bloodstream in a manner generally thought to be similar to the enzymatic clearance of naturally produced chylomicrons formed after enteral fat intake. The triglycerides are hydrolyzed to free fatty acids and glycerol by the enzyme lipoprotein lipase. In the liver, circulating free fatty acids are oxidized or converted to very low density lipoproteins by hepatic lipase that re-enter the bloodstream. </metabolism>
  <absorption>Following infusion, there is a transient increase in plasma triglycerides.</absorption>
  <half-life/>
  <protein-binding>Free fatty acids circulate in the plasma, bound to albumin. </protein-binding>
  <route-of-elimination>Converted carbon dioxide from smaller fatty acid units are excreted by the lungs. </route-of-elimination>
  <volume-of-distribution>After triglycerides are hydrolyzed, fatty acids can enter the tissues where they may be oxidized or resynthesized into triglcerides and stored. </volume-of-distribution>
  <clearance>The elimination rate of lipid emulsions depends on particle size, fatty acid composition, apolipoprotein content of the lipid globules, lipoprotein lipase activity, and hepatic lipase activity [L854].</clearance>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>10% Travamulsion Liq IV</name>
      <labeller>Baxter Corporation Clintec Nutrition Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02016028</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2015-08-05</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>20% Travamulsion Liq IV</name>
      <labeller>Baxter Corporation Clintec Nutrition Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02016036</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2015-08-05</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Clinoleic 20%</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02344327</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Clinolipid</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-9540</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA204508</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Colip 20%</name>
      <labeller>Baxter Corporation Clintec Nutrition Division</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230772</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-10-07</started-marketing-on>
      <ended-marketing-on>2007-08-02</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>essenHERB Soybean 90 Deep Cleansing</name>
      <labeller>Ami Cosmetic Co.,Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>59535-1661</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Oil</dosage-form>
      <strength>91.6 g/100mL</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Intralipid</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-0520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength>30 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA019942</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Intralipid</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-0519</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-04-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength>20 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA020248</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Intralipid</name>
      <labeller>HF Acquisition Co LLC, DBA HealthFirst</labeller>
      <ndc-id/>
      <ndc-product-code>51662-1333</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-12-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength>20 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA018449</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Intralipid</name>
      <labeller>Baxter Healthcare CORP</labeller>
      <ndc-id/>
      <ndc-product-code>0338-0518</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength>10 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA017643</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Intralipid 10%</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02065681</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Intralipid 20%</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02065673</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Intralipid 30%</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02216175</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Kabiven</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-712</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA200656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Liposyn II</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-9786</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-08-27</started-marketing-on>
      <ended-marketing-on>2011-02-01</ended-marketing-on>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA018997</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Liposyn II</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-9789</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-08-27</started-marketing-on>
      <ended-marketing-on>2011-02-01</ended-marketing-on>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA018991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Liposyn II 10%</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00720976</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2014-08-01</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Liposyn II 20%</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00720968</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2014-08-01</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Liposyn II Inj 10%</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00818712</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-01-01</started-marketing-on>
      <ended-marketing-on>2014-08-01</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Liposyn III</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-9790</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-09-24</started-marketing-on>
      <ended-marketing-on>2011-07-01</ended-marketing-on>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA018969</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Liposyn III</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-6892</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-05-01</started-marketing-on>
      <ended-marketing-on>2011-06-01</ended-marketing-on>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA020181</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Liposyn III</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-9791</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-09-25</started-marketing-on>
      <ended-marketing-on>2011-07-01</ended-marketing-on>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA018970</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Liposyn III 10%</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02366800</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on>2016-07-29</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Liposyn III 20%</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02366819</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on>2016-07-29</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>No name provided</name>
      <labeller>Shanghai Kejing Cleaning Products Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>31190-230</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part352</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NutriLipid I.V. Fat Emulsion</name>
      <labeller>B. Braun Medical Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0264-4460</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>20 g/100mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA019531</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Olimel 3.3% E</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352508</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Olimel 4.4%</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352524</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Olimel 4.4% E</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352516</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Olimel 5.7%</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352540</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Olimel 5.7% E</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352532</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-01-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Olimel 7.6%</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02477947</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Olimel 7.6% E</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02477955</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Perikabiven</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-714</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA200656</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Periolimel 2.5% E</name>
      <labeller>Baxter Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02352494</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Phytolecithine D</name>
      <labeller>Phyto Health Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00290912</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>2003-11-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Smofkabiven</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02440695</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Smofkabiven Electrolyte Free</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02440687</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-09-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Smofkabiven Peripheral</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456206</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Smoflipid</name>
      <labeller>Fresenius Kabi USA, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63323-820</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA207648</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Smoflipid 20%</name>
      <labeller>Fresenius Kabi</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02396963</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>SPF 30 Sunscreen</name>
      <labeller>Shanghai Kejing Cleaning Products Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>31190-330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part352</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Liposyn III</name>
      <ingredients>Egg phospholipids + Glycerin + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>essenHERB Soybean 90 Deep Cleansing</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>No name provided</name>
      <ingredients>Octinoxate + Octisalate + Oxybenzone + Soybean oil + Titanium dioxide</ingredients>
    </mixture>
    <mixture>
      <name>SPF 30 Sunscreen</name>
      <ingredients>Octinoxate + Octisalate + Oxybenzone + Soybean oil + Titanium dioxide</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn III</name>
      <ingredients>Egg phospholipids + Glycerin + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn III</name>
      <ingredients>Egg phospholipids + Glycerin + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Intralipid</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Kabiven</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Calcium chloride + D-glucose + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium sulfate + Methionine + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Perikabiven</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Calcium chloride + D-glucose + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium sulfate + Methionine + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>NutriLipid I.V. Fat Emulsion</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Intralipid</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Intralipid</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Intralipid</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Smoflipid</name>
      <ingredients>Fish oil + Medium-chain triglycerides + Olive oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Clinolipid</name>
      <ingredients>Olive oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Intralipid 10%</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Clinoleic 20%</name>
      <ingredients>Olive oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Phytolecithine D</name>
      <ingredients>Soybean + Soybean oil + Vitamin D</ingredients>
    </mixture>
    <mixture>
      <name>10% Travamulsion Liq IV</name>
      <ingredients>Egg phospholipids + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>20% Travamulsion Liq IV</name>
      <ingredients>Egg phospholipids + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II Inj 10%</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Colip 20%</name>
      <ingredients>Medium-chain triglycerides + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II 20%</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II 10%</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Intralipid 20%</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Smoflipid 20%</name>
      <ingredients>Medium-chain triglycerides + Olive oil + Omega-3 fatty acids + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Intralipid 30%</name>
      <ingredients>Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Periolimel 2.5% E</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Calcium chloride + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium chloride + Methionine + Olive oil + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Olimel 4.4% E</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Calcium chloride + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium chloride + Methionine + Olive oil + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Olimel 5.7% E</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Calcium chloride + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium chloride + Methionine + Olive oil + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Smofkabiven Electrolyte Free</name>
      <ingredients>Alanine + Arginine + Dextrose, unspecified form + Fish oil + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Medium-chain triglycerides + Methionine + Nitrogen + Olive oil + Phenylalanine + Proline + Serine + Soybean oil + Taurine + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Smofkabiven</name>
      <ingredients>Alanine + Arginine + Calcium chloride + Dextrose, unspecified form + Fish oil + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium sulfate + Medium-chain triglycerides + Methionine + Nitrogen + Olive oil + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Taurine + Threonine + Tryptophan + Tyrosine + Valine + Zinc sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Olimel 3.3% E</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Calcium chloride + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium chloride + Methionine + Olive oil + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn III 10%</name>
      <ingredients>Egg phospholipids + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn III 20%</name>
      <ingredients>Egg phospholipids + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Smofkabiven Peripheral</name>
      <ingredients>Alanine + Arginine + Calcium chloride + Dextrose, unspecified form + Fish oil + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium sulfate + Medium-chain triglycerides + Methionine + Olive oil + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Taurine + Threonine + Tryptophan + Tyrosine + Valine + Zinc sulfate</ingredients>
    </mixture>
    <mixture>
      <name>Olimel 4.4%</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Methionine + Olive oil + Phenylalanine + Proline + Serine + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Olimel 5.7%</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Methionine + Olive oil + Phenylalanine + Proline + Serine + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Olimel 7.6% E</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Calcium chloride + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Magnesium chloride + Methionine + Olive oil + Phenylalanine + Potassium chloride + Proline + Serine + Sodium acetate + Sodium glycerophosphate + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
    <mixture>
      <name>Olimel 7.6%</name>
      <ingredients>Alanine + Arginine + Aspartic acid + Dextrose, unspecified form + Glutamic acid + Glycine + Histidine + Isoleucine + L-Lysine + Leucine + Methionine + Olive oil + Phenylalanine + Proline + Serine + Soybean oil + Threonine + Tryptophan + Tyrosine + Valine</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Biological Products</category>
      <mesh-id>D001688</mesh-id>
    </category>
    <category>
      <category>Caloric Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Complex Mixtures</category>
      <mesh-id>D045424</mesh-id>
    </category>
    <category>
      <category>Diet, Food, and Nutrition</category>
      <mesh-id>D000066888</mesh-id>
    </category>
    <category>
      <category>Dietary Fats</category>
      <mesh-id>D004041</mesh-id>
    </category>
    <category>
      <category>Dietary Fats, Unsaturated</category>
      <mesh-id>D004042</mesh-id>
    </category>
    <category>
      <category>Fats</category>
      <mesh-id>D005223</mesh-id>
    </category>
    <category>
      <category>Fats, Unsaturated</category>
      <mesh-id>D005224</mesh-id>
    </category>
    <category>
      <category>Food</category>
      <mesh-id>D005502</mesh-id>
    </category>
    <category>
      <category>Food and Beverages</category>
      <mesh-id>D019602</mesh-id>
    </category>
    <category>
      <category>Lipid Emulsion</category>
      <mesh-id/>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Oils</category>
      <mesh-id>D009821</mesh-id>
    </category>
    <category>
      <category>Physiological Phenomena</category>
      <mesh-id>D010829</mesh-id>
    </category>
    <category>
      <category>Plant Oils</category>
      <mesh-id>D010938</mesh-id>
    </category>
    <category>
      <category>Plant Preparations</category>
      <mesh-id>D028321</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Liquid</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Emulsion</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Oil</form>
      <route>Topical</route>
      <strength>91.6 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Emulsion</form>
      <route>Intravenous</route>
      <strength>10 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Emulsion</form>
      <route>Intravenous</route>
      <strength>20 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Emulsion</form>
      <route>Intravenous</route>
      <strength>30 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Emulsion</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, emulsion</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>20 g/100mL</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>40:20.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents>
    <patent>
      <number>5840757</number>
      <country>United States</country>
      <approved>1998-11-24</approved>
      <expires>2015-11-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9717852</number>
      <country>United States</country>
      <approved>2017-08-01</approved>
      <expires>2033-04-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>3289</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910452</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Soybean_oil</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000071</id>
      <name>Peroxisome proliferator-activated receptor alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A19591</ref-id>
            <pubmed-id>16651709</pubmed-id>
            <citation>Nishimura M, Yamaguchi M, Naito S, Yamauchi A: Soybean oil fat emulsion to prevent TPN-induced liver damage: possible molecular mechanisms and clinical implications. Biol Pharm Bull. 2006 May;29(5):855-62.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q07869" source="Swiss-Prot">
        <name>Peroxisome proliferator-activated receptor alpha</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2.</specific-function>
        <gene-name>PPARA</gene-name>
        <locus>22q12-q13.1|22q13.31</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.2</theoretical-pi>
        <molecular-weight>52224.595</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9232</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PPARA</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L02932</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307341</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>593</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q07869</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PPARA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NR1C1</synonym>
          <synonym>Nuclear receptor subfamily 1 group C member 1</synonym>
          <synonym>PPAR</synonym>
          <synonym>PPAR-alpha</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000142|Peroxisome proliferator-activated receptor alpha
MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFGFTEYQYLGSC
PGSDGSVITDTLSPASSPSSVTYPVVPGSVDESPSGALNIECRICGDKASGYHYGVHACE
GCKGFFRRTIRLKLVYDKCDRSCKIQKKNRNKCQYCRFHKCLSVGMSHNAIRFGRMPRSE
KAKLKAEILTCEHDIEDSETADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFV
IHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANL
DLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFD
FAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDI
FLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021925|Peroxisome proliferator-activated receptor alpha (PPARA)
ATGGTGGACACGGAAAGCCCACTCTGCCCCCTCTCCCCACTCGAGGCCGGCGATCTAGAG
AGCCCGTTATCTGAAGAGTTCCTGCAAGAAATGGGAAACATCCAAGAGATTTCGCAATCC
ATCGGCGAGGATAGTTCTGGAAGCTTTGGCTTTACGGAATACCAGTATTTAGGAAGCTGT
CCTGGCTCAGATGGCTCGGTCATCACGGACACGCTTTCACCAGCTTCGAGCCCCTCCTCG
GTGACTTATCCTGTGGTCCCCGGCAGCGTGGACGAGTCTCCCAGTGGAGCATTGAACATC
GAATGTAGAATCTGCGGGGACAAGGCCTCAGGCTATCATTACGGAGTCCACGCGTGTGAA
GGCTGCAAGGGCTTCTTTCGGCGAACGATTCGACTCAAGCTGGTGTATGACAAGTGCGAC
CGCAGCTGCAAGATCCAGAAAAAGAACAGAAACAAATGCCAGTATTGTCGATTTCACAAG
TGCCTTTCTGTCGGGATGTCACACAACGCGATTCGTTTTGGACGAATGCCAAGATCTGAG
AAAGCAAAACTGAAAGCAGAAATTCTTACCTGTGAACATGACATAGAAGATTCTGAAACT
GCAGATCTCAAATCTCTGGCCAAGAGAATCTACGAGGCCTACTTGAAGAACTTCAACATG
AACAAGGTCAAAGCCCGGGTCATCCTCTCAGGAAAGGCCAGTAACAATCCACCTTTTGTC
ATACATGATATGGAGACACTGTGTATGGCTGAGAAGACGCTGGTGGCCAAGCTGGTGGCC
AATGGCATCCAGAACAAGGAGGCGGAGGTCCGCATCTTTCACTGCTGCCAGTGCACGTCA
GTGGAGACCGTCACGGAGCTCACGGAATTCGCCAAGGCCATCCCAGGCTTCGCAAACTTG
GACCTGAACGATCAAGTGACATTGCTAAAATACGGAGTTTATGAGGCCATATTCGCCATG
CTGTCTTCTGTGATGAACAAAGACGGGATGCTGGTAGCGTATGGAAATGGGTTTATAACT
CGTGAATTCCTAAAAAGCCTAAGGAAACCGTTCTGTGATATCATGGAACCCAAGTTTGAT
TTTGCCATGAAGTTCAATGCACTGGAACTGGATGACAGTGATATCTCCCTTTTTGTGGCT
GCTATCATTTGCTGTGGAGATCGTCCTGGCCTTCTAAACGTAGGACACATTGAAAAAATG
CAGGAGGGTATTGTACATGTGCTCAGACTCCACCTGCAGAGCAACCACCCGGACGATATC
TTTCTCTTCCCAAAACTTCTTCAAAAAATGGCAGACCTCCGGCAGCTGGTGACGGAGCAT
GCGCAGCTGGTGCAGATCATCAAGAAGACGGAGTCGGATGCTGCGCTGCACCCGCTACTG
CAGGAGATCTACAGGGACATGTACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00104</identifier>
            <name>Hormone_recep</name>
          </pfam>
          <pfam>
            <identifier>PF00105</identifier>
            <name>zf-C4</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II core promoter proximal region sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II repressing transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional activator activity, RNA polymerase II transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin conjugating enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>enamel mineralization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fatty acid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of appetite</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cholesterol storage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glycolytic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of leukocyte cell-cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of macrophage derived foam cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of pri-miRNA transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of receptor biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequestering of triglyceride</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription regulatory region DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fatty acid beta-oxidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fatty acid oxidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gluconeogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cellular ketone metabolic process by positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of glycolytic process by positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of lipid transport by positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to insulin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription initiation from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>